Literature DB >> 26109734

Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell Dysfunction.

Archana Panikkar1, Corey Smith2, Andrew Hislop3, Nick Tellam4, Vijayendra Dasari4, Kristin A Hogquist5, Michelle Wykes4, Denis J Moss4, Alan Rickinson3, Henry H Balfour6, Rajiv Khanna2.   

Abstract

Here we present evidence for previously unappreciated B-cell immune dysregulation during acute Epstein-Barr virus (EBV)-associated infectious mononucleosis (IM). Longitudinal analyses revealed that patients with acute IM have undetectable EBV-specific neutralizing antibodies and gp350-specific B-cell responses, which were associated with a significant reduction in memory B cells and no evidence of circulating antibody-secreting cells. These observations correlate with dysregulation of tumor necrosis factor family members BAFF and APRIL and increased expression of FAS on circulating B cells.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26109734      PMCID: PMC4524077          DOI: 10.1128/JVI.01293-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

2.  Neutralizing antibodies to Epstein-Barr virus in healthy populations and patients with infectious mononucleosis.

Authors:  J F Hewetson; G Rocchi; W Henle; G Henle
Journal:  J Infect Dis       Date:  1973-09       Impact factor: 5.226

3.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

4.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

5.  Regulated expression of BAFF-binding receptors during human B cell differentiation.

Authors:  Jaime R Darce; Bonnie K Arendt; Xiaosheng Wu; Diane F Jelinek
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

6.  Life-threatening infectious mononucleosis: is it correlated with virus-induced T cell proliferation?

Authors:  E Baumgarten; H Herbst; M Schmitt; K H Seeger; U Schulte-Overberg; G Henze
Journal:  Clin Infect Dis       Date:  1994-07       Impact factor: 9.079

7.  Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students.

Authors:  Henry H Balfour; Oludare A Odumade; David O Schmeling; Beth D Mullan; Julie A Ed; Jennifer A Knight; Heather E Vezina; William Thomas; Kristin A Hogquist
Journal:  J Infect Dis       Date:  2012-10-24       Impact factor: 5.226

8.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

Review 9.  Epstein-barr virus vaccines.

Authors:  Jeffrey I Cohen
Journal:  Clin Transl Immunology       Date:  2015-01-23

10.  Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells.

Authors:  Melanie Rauch; Roxane Tussiwand; Nabil Bosco; Antonius G Rolink
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

View more
  8 in total

1.  Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Authors:  Wei Bu; Gregory M Hayes; Hui Liu; Lorraine Gemmell; David O Schmeling; Pierce Radecki; Fiona Aguilar; Peter D Burbelo; Jennifer Woo; Henry H Balfour; Jeffrey I Cohen
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.

Authors:  Eric R Weiss; Galit Alter; Javier Gordon Ogembo; Jennifer L Henderson; Barbara Tabak; Yasin Bakiş; Mohan Somasundaran; Manuel Garber; Liisa Selin; Katherine Luzuriaga
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

Review 3.  Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.

Authors:  David Baker; Monica Marta; Gareth Pryce; Gavin Giovannoni; Klaus Schmierer
Journal:  EBioMedicine       Date:  2017-01-31       Impact factor: 8.143

Review 4.  Human immunity against EBV-lessons from the clinic.

Authors:  Stuart G Tangye; Umaimainthan Palendira; Emily S J Edwards
Journal:  J Exp Med       Date:  2017-01-20       Impact factor: 14.307

Review 5.  Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8+ T Cell Survival, Differentiation, and Function.

Authors:  Jennifer L Cannons; Silvia Preite; Senta M Kapnick; Gulbu Uzel; Pamela L Schwartzberg
Journal:  Front Immunol       Date:  2018-08-02       Impact factor: 7.561

6.  Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.

Authors:  Barbara Serafini; Barbara Rosicarelli; Caterina Veroni; Gina Adriana Mazzola; Francesca Aloisi
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

7.  Evolution of functional antibodies following acute Epstein-Barr virus infection.

Authors:  Christina B Karsten; Yannic C Bartsch; Sally A Shin; Matthew D Slein; Howard M Heller; Kumaran Kolandaivelu; Jaap M Middeldorp; Galit Alter; Boris Julg
Journal:  PLoS Pathog       Date:  2022-09-06       Impact factor: 7.464

Review 8.  Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.

Authors:  Jean-Marie Carpier; Carrie L Lucas
Journal:  Front Immunol       Date:  2018-01-16       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.